Archives of rheumatology最新文献

{"title":"Epidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure database.","authors":"Emine Duygu Ersözlü, Mustafa Ekici, Belkis Nihan Coşkun, Suade Özlem Badak, Emre Bilgin, Umut Kalyoncu, Burcu Yağız, Yavuz Pehlivan, Orhan Küçükşahin, Abdulsamet Erden, Dilek Solmaz, Pamir Atagündüz, Gezmiş Kimyon, Cemal Beş, Seda Çolak, Rıdvan Mercan, Timuçin Kaşifoğlu, Hakan Emmungil, Nilüfer Alpay Kanıtez, Aşkın Ateş, Süleyman Serdar Koca, Sedat Kiraz, İhsan Ertenli","doi":"10.46497/ArchRheumatol.2023.9504","DOIUrl":"10.46497/ArchRheumatol.2023.9504","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate the hepatitis B (HBV) and C (HCV) frequency and clinical characteristics among patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) who receive biological treatments.</p><p><strong>Patients and methods: </strong>The observational study was conducted with patients from the TReasure database, a web-based prospective observational registry collecting data from 17 centers across Türkiye, between December 2017 and June 2021. From this database, 3,147 RA patients (2,502 males, 645 females; median age 56 years; range, 44 to 64 years) and 6,071 SpA patients (2,709 males, 3,362 females; median age 43 years; range, 36 to 52 years) were analyzed in terms of viral hepatitis, patient characteristics, and treatments used.</p><p><strong>Results: </strong>The screening rate for HBV was 97% in RA and 94.2% in SpA patients. Hepatitis B surface antigen (HBsAg) positivity rates were 2.6% and 2%, hepatitis B surface antibody positivity rates were 32.3% and 34%, hepatitis B core antibody positivity rates were 20.3% and 12.5%, HBV DNA (deoxyribonucleic acid) positivity rates were 3.5% and 12.5%, and antibody against HCV positivity rates were 0.8% and 0.3% in RA and SpA patients, respectively. The HBsAg-positive patients were older and had more comorbidities, including hypertension, diabetes, and coronary artery disease. In addition, rheumatoid factor (RF) positivity was more common in HBsAg-positive cases. The most frequently prescribed biologic disease-modifying antirheumatic drugs were adalimumab (28.5%), etanercept (27%), tofacitinib (23.4%), and tocilizumab (21.5%) in the RA group and adalimumab (48.1%), etanercept (31.4%), infliximab (22.6%), and certolizumab (21.1%) in the SpA group. Hepatitis B reactivation was observed in one RA patient during treatment, who received rituximab and prophylaxis with tenofovir.</p><p><strong>Conclusion: </strong>The epidemiological characteristics of patients with rheumatic diseases and viral hepatitis are essential for effective patient management. This study provided the most recent epidemiological characteristics from the prospective TReasure database, one of the comprehensive registries in rheumatology practice.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the COVID-19 pandemic on the routine of an infusion center of immunobiologicals from a Brazilian University Hospital.","authors":"Thelma Skare, Maria Dorl, Mylene Cordeiro, Barbara Kahlow, Renato Nisihara","doi":"10.46497/ArchRheumatol.2023.9955","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.9955","url":null,"abstract":"","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards a consensus on the clinical applications and interpretations of the nailfold capillaroscopy standards in clinical practice: An initiative by the Egyptian Society of Microcirculation.","authors":"Yasser El Miedany, Sherif Ismail, Mary Wadie Fawzy, Ulf Müller-Ladner, Roberto Giacomelli, Vasiliki Liakouli, W Hermann, Nihal Fathy, Maha El Gaafary, Nermin A Fouad, Sally Saber, Mohammed Hassan Abu-Zaid","doi":"10.46497/ArchRheumatol.2023.9875","DOIUrl":"10.46497/ArchRheumatol.2023.9875","url":null,"abstract":"<p><strong>Objectives: </strong>Based on the mainstream adoption of nailfold capillaroscopy as an investigative tool for rheumatologists, this work was carried out by a panel of experts in the field of capillaroscopy and microcirculation to issue a consensus view on capillaroscopic image acquisition and analysis standardization.</p><p><strong>Patients and methods: </strong>After the key clinical questions were identified by the core team, a systematic review of the published research was carried out focusing on variable capillaroscopic techniques, definitions, and characteristics, including capillary density (number of capillaries), capillary morphology (shape of each capillary), capillary dimensions (width of apical, arterial, and venous limb of the capillary), and the presence of hemorrhages. The expert panel attained a consensus and developed recommendations for the standardization of capillaroscopy in clinical practice. These included recommendations for normality and abnormality and the different capillaroscopic patterns. It also involved recommendations for scoring systems, reliability, and reporting.</p><p><strong>Results: </strong>A panel of 11 experts participated in the two rounds with a response rate of 100%. A total of nine recommendations were obtained. The agreement with the recommendations (a score of 7-9) ranged from 81.8 to 90.9%. A consensus (i.e., ≥75% of respondents strongly agreed or agreed) was reached on all the clinical standards.</p><p><strong>Conclusion: </strong>This work highlighted the main NFC indications, the technical equipment that should be used, how to carry out the procedure, standardization of the terminology of the parameters, and the interpretation of NFC findings. An evidence-based consensus incorporating the advice and experience of a diverse international expert panel was reached.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A clinical analysis of hemophagocytic syndrome secondary to autoimmune diseases.","authors":"Yang Liu, Qian Li, Yazhen Su, Guozhu Che, Ying Liu, Pengyan Qiao, Sumiao Liu, Ke Xu","doi":"10.46497/ArchRheumatol.2023.9728","DOIUrl":"10.46497/ArchRheumatol.2023.9728","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to analyze the differences of etiologies and clinical features between patients with autoimmune-associated hemophagocytic syndrome (AAHS) and those with other underlying diseases of hemophagocytic syndrome (HPS).</p><p><strong>Patients and methods: </strong>The retrospective study was performed with 130 HPS patients (70 males, 60 females; mean age: 50.4±18.1 years; range, 13 to 85 years) between January 1^st, 2011, and April 1^st, 2022. The patients fulfilled at least five of the eight criteria proposed by the Histiocytosis Society in 2004. The underlying diseases related to HPS were divided into four categories: autoimmune, infection, malignancy and idiopathic diseases. And the clinical manifestations, laboratory examinations, treatments, and prognosis were analyzed respectively.</p><p><strong>Results: </strong>Nineteen (14.6%) patients had AAHS, 45 (34.6%) had infection-associated HPS, 57 (43.8%) had malignancy-associated HPS, and nine (6.9%) had idiopathic HPS. The most common symptoms of HPS were unremitting fever in 123 (94.6%) of 130 patients and splenomegaly in 92 (70.8%). All patients manifested a decline of at least two lineages of hematopoietic cells. The absolute values of T cells and B cells of AAHS were significantly higher than that of malignancy-associated HPS. The levels of soluble CD25 (interleukin-2 receptor) of AAHS were the lowest among all-cause HPS (p<0.05). The all-cause mortality rate of hospitalized patients with HPS was 46.2%. The patients with AAHS had a better prognosis compared to other etiologies (odds ratio [OR]=0.091, 95% confidence interval [CI]: 0.011-0.775, p=0.028). Epstein-Barr virus infection (OR=4.761, 95% CI: 1.619-14.004, p=0.005) and pulmonary involvement (OR=4.555 95% CI: 1.524-13.609, p=0.007) were independent predictors of poor outcome in HPS. Thrombocytopenia (OR=0.978, 95% CI: 0.968-0.999, p=0.040) had a boundary effect on prognosis.</p><p><strong>Conclusion: </strong>Patients with HPS secondary to autoimmune disease have better outcomes compared to patients complicated with Epstein-Barr virus infection or pulmonary involvement.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare condition in Takayasu arteritis: Renal amyloidosis.","authors":"Semih Gülle, Ömer Komaç, Gerçek Can, Fatoş Önen","doi":"10.46497/ArchRheumatol.2023.9893","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.9893","url":null,"abstract":"","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pericardial effusion in children admitted with juvenile idiopathic arthritis: A multicenter retrospective cohort study from the pediatric health information system.","authors":"Daniel Fiedorek, Xinyu Tang, Sukesh Sukumaran, R Thomas Collins, Elijah Bolin","doi":"10.46497/ArchRheumatol.2023.9690","DOIUrl":"10.46497/ArchRheumatol.2023.9690","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to determine if the presence of a pericardial effusion is associated with adverse outcomes among children admitted with juvenile idiopathic arthritis.</p><p><strong>Patients and methods: </strong>The multicenter, retrospective cohort study was conducted with 4,332 patients (1,554 males, 2,778 females; median age: 12 years; IQR, 7, 15 years) using the Pediatric Health Information System. Data from hospital admissions between January 1, 2004, and September 15, 2015, were obtained for patients with an International Disease Classification, Ninth Revision code for juvenile idiopathic arthritis. Pericardial effusion was the primary predictor variable; the outcomes of interest were length of stay, hospital costs, and readmission within 90 days. Multivariate models were created to evaluate associations between pericardial effusion and adverse outcomes. We also analyzed factors associated with increased odds of having pericardial effusion in juvenile idiopathic arthritis.</p><p><strong>Results: </strong>One hundred twenty (3%) patients had a code for pericardial effusion. Children with pericardial effusion had a longer median length of stay (7 days (IQR 3, 12) <i>vs.</i> 3 days (IQR 2,6), p<0.001), higher median costs ($17,688 (IQR 8,657, 40,623) <i>vs.</i> $8,456 (IQR 4,865, 16,302), p<0.001), and greater rates of readmission (22% <i>vs.</i> 15%, p=0.045). Multivariate analysis demonstrated no significant association between pericardial effusion and outcomes of interest. Black race and male sex were associated with increased odds of having pericardial effusion.</p><p><strong>Conclusion: </strong>Pericardial effusion is rare among children admitted with juvenile idiopathic arthritis but is associated with significant morbidity; its presence may be a marker of disease severity. Black children and males admitted with juvenile idiopathic arthritis warrant special consideration and may benefit from screening echocardiography.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of treatment outcomes in patients with antineutrophil cytoplasmic antibody-associated vasculitis on rituximab therapy.","authors":"Tsvetelina Yoneva, Yana Zdravkova, Georgi Kotov, Ekaterina Ivanova Todorova, Georgi Vasilev, Rasho Rashkov, Ivan Sheytanov","doi":"10.46497/ArchRheumatol.2023.9556","DOIUrl":"10.46497/ArchRheumatol.2023.9556","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to analyze a group of patients with severe and refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) managed with rituximab and to report on treatment outcomes.</p><p><strong>Patients and methods: </strong>A total of 78 patients (41 females, 37 males; mean age: 50.1±13.4 years; range, 18 to 76 years) with AAV on rituximab treatment were included in the single-center, retrospective study conducted between 2009 and 2018. The diagnosis was established based on the 1990 classification criteria of the American College of Rheumatology and the definitions of vasculitis of Chapel Hill Consensus Conference. Laboratory and immunological tests were conducted. Disease activity was determined through the Birmingham Vasculitis Activity Score.</p><p><strong>Results: </strong>Rituximab was preferred over cyclophosphamide in 37 patients and used as a second-line therapy after cyclophosphamide in 41 cases. Rituximab treatment showed favorable outcomes with regard to serum creatinine levels, proteinuria, and hematuria, as well as in cases of isolated lung involvement. Nearly half of patients with pulmonary renal syndrome also improved, with 22.2% achieving remission. ANCAs were positive in 85.9% of patients at the onset of rituximab treatment and became negative in 82% of the positive cases. Adverse events were rare and included infusion reactions (one case of reactivation of a herpes zoster infection and one case of allergic reaction).</p><p><strong>Conclusion: </strong>Rituximab is an efficient and safe therapeutic option in patients with AAV who are difficult to treat, have insufficient response, or have not tolerated other treatments.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solitary syndesmophyte in odontoid process of a patient with ankylosing spondylitis.","authors":"Hong Ki Min, Se Hee Kim, Hae-Rim Kim, Sang-Heon Lee","doi":"10.46497/ArchRheumatol.2023.9880","DOIUrl":"10.46497/ArchRheumatol.2023.9880","url":null,"abstract":"A 22-year-old male patient was admitted to the rheumatology clinic due to neck and back pain with morning stiffness for 12 months. He suffered from right knee and heel pain six months ago. He showed increased levels of high-sensitivity C-reactive protein (2.20 mg/dL, reference range: 0.01-0.3 mg/dL) and erythrocyte sedimentation rate (67 mm/h, reference range: 0-15 mm/h). To evaluate neck and back pain, the physician performed computed tomography (CT) of the whole spine. The CT finding was absence for herniated nucleus pulposus nor neural foramen stenosis. All vertebral corners of whole spine were clear (Figure 1a), except for bony spur at odontoid process of C2 (Figure 1b, white arrow).","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the efficacy and safety of oligomeric proanthocyanidins and nifedipine in patients with primary Raynaud's phenomenon: An open-label, randomized, prospective pilot study.","authors":"Kyung-Ann Lee, Seung-Hwan Jung, Jong-Sun Kim, Hyun-Sook Kim","doi":"10.46497/ArchRheumatol.2023.9212","DOIUrl":"10.46497/ArchRheumatol.2023.9212","url":null,"abstract":"","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689017/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GCSB-5 regulates inflammatory arthritis and pain by modulating the mitogen-activated protein kinase signaling pathway in a murine model of rheumatoid arthritis.","authors":"Jihye Bang, Gyeonghwa Kim, Soo Young Park, Hye Ra Jung, Sang-Hyon Kim, Ji-Min Kim","doi":"10.46497/ArchRheumatol.2023.9643","DOIUrl":"https://doi.org/10.46497/ArchRheumatol.2023.9643","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to determine whether GCSB-5 has anti-inflammatory and antinociceptive effects in mice with collagen-induced arthritis (CIA), an animal model of rheumatoid arthritis (RA), and investigate the influence of GCSB-5 on the mitogen-activated protein kinase (MAPK) pathway.</p><p><strong>Materials and methods: </strong>The experimental animal study was designed to include five groups: CIA mice treated with GCSB-5 (300 mg/kg), GCSB-5 (600 mg/kg), celecoxib (60 mg/kg), or saline for four weeks, and nontreated control mice. The clinical severity of arthritis was scored. Nociceptive thresholds were measured by using a von Frey dynamic plantar analgesimeter. The MAPK pathway was evaluated in mouse synovium. The expression of channels associated with pain signaling was assessed by western blot and immunohistochemical staining.</p><p><strong>Results: </strong>GCSB-5 treatment diminished the severity of clinical arthritis and increased the nociceptive threshold in mice with CIA. Celecoxib, a positive control drug, also showed comparable changes. Clinical arthritis scores were inversely related to mechanical thresholds. GCSB-5 administration decreased the levels of anti-type II collagen antibody and inflammatory cytokines in the sera of mice with CIA. Furthermore, ERK, p38 MAPK, and JNK phosphorylation were downregulated and TRPV1 and ASIC3 expression were decreased in the synovium of GCSB-5-treated mice compared to salinetreated mice. Interleukin-6-induced TRPV1 and ASIC3 upregulation were also inhibited by GCSB-5 in human RA fibroblast-like synoviocytes <i>in vitro</i>.</p><p><strong>Conclusion: </strong>GCSB-5 decreased inflammatory arthritis and pain in a murine model of RA. The results present evidence that GCSB-5 may be beneficial for relieving pain as well as decreasing inflammation in autoimmune arthritis, such as RA.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}